<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="7c67c2d2-59fd-423a-b446-a528f43a0916"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use PHEXX<sup>®</sup> safely and effectively. See full prescribing information for PHEXX.<br/>
      <br/> PHEXX (lactic acid, citric acid, and potassium bitartrate) vaginal gel<br/>
      <br/> Initial U.S. Approval: 2020</title>
   <effectiveTime value="20250502"/>
   <setId root="14b01a15-9b47-4be3-bb2e-a2010eab429e"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="832466119" root="1.3.6.1.4.1.519.1"/>
            <name>Evofem, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="5dcace03-3969-4c18-b379-bc5a0cbc7664"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250502"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="69751-101" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Phexx</name>
                        <formCode code="C42934" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GEL"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>lactic acid, L-, citric acid monohydrate, and potassium bitartrate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="90" unit="mg"/>
                              <denominator value="5" unit="g"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="F9S9FFU82N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTIC ACID, L-</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="F9S9FFU82N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTIC ACID, L-</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="50" unit="mg"/>
                              <denominator value="5" unit="g"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="XF417D3PSL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ANHYDROUS CITRIC ACID</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="20" unit="mg"/>
                              <denominator value="5" unit="g"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="NPT6P8P3UU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM BITARTRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="W4888I119H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TARTARIC ACID</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69751-101-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43166" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="APPLICATOR"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="12" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="69751-101-12" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20200901"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA208352" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200801"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>off-white to tan</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38313" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VAGINAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="f16ea894-06c0-4e65-96dd-0d867b286ccd"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>PHEXX is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.</paragraph>
               </text>
               <effectiveTime value="20250502"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>PHEXX is a combination of lactic acid, citric acid, and potassium bitartrate indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                        <paragraph>Limitations of Use: PHEXX is not effective for the prevention of pregnancy when administered after intercourse.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="65c4afab-ee73-42f1-89f6-03d3ecca642d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>PHEXX is not effective for the prevention of pregnancy when administered after intercourse [<content styleCode="italics">see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="bd7cff01-5a9e-44d3-a634-d99c2bdc5808"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250502"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Administer one (<linkHtml href="#S1">1</linkHtml>) pre-filled single-dose applicator of PHEXX (5 grams) vaginally immediately before (or up to one hour before) each episode of vaginal intercourse (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>May use during any part of the menstrual cycle (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="27678a19-2134-4c39-b0c7-d994b814353d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage</title>
                     <text>
                        <paragraph>Administer one pre-filled applicator of PHEXX (5 grams) vaginally immediately <content styleCode="bold">before</content> or up to one hour <content styleCode="bold">before</content> each act of vaginal intercourse. If more than one act of vaginal intercourse occurs within one hour, an additional dose must be applied. Five grams of PHEXX contains 90 mg of lactic acid, 50 mg of citric acid, and 20 mg of potassium bitartrate.</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="286a97b0-a850-48ce-ab85-1548d0e09998"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Timing of PHEXX Use</title>
                     <text>
                        <paragraph>May use PHEXX during any part of the menstrual cycle. May use PHEXX as soon as it is safe to resume vaginal intercourse after childbirth, abortion, or miscarriage.</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="b4c41aec-7887-4771-88a8-153a5532affb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Use of PHEXX with Other Contraceptive Methods</title>
                     <text>
                        <paragraph>PHEXX may be used concomitantly with hormonal contraceptives; latex, polyurethane, and polyisoprene condoms; and vaginal diaphragms. Avoid PHEXX use with vaginal rings.</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="b5947110-0e6c-458e-a0f9-f8295878d287"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Use of PHEXX with Other Vaginal Products</title>
                     <text>
                        <paragraph>PHEXX may be used concomitantly with other products for vaginal infections including miconazole, metronidazole, and tioconazole.</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="d45b6bd6-3c98-4718-871c-99ee6a724807"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Vaginal gel: 18 mg of lactic acid, 10 mg of citric acid, and 4 mg of potassium bitartrate in each gram (1.8%, 1%, and 0.4%, respectively) of off-white to tan color gel supplied in a pre-filled single-dose (5 grams) vaginal applicator</paragraph>
               </text>
               <effectiveTime value="20250502"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Each pre-filled single-dose vaginal applicator delivers 5 grams of gel containing lactic acid (1.8%), citric acid (1%), and potassium bitartrate (0.4%). (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="ea85dcf1-8aaf-4e4c-9ebd-8ee30840a62c"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250502"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Cystitis and Pyelonephritis: Avoid use in women with a history of recurrent UTI or urinary tract abnormalities (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="fae79a1f-b3d5-419c-9ac6-191eba84198c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Cystitis and Pyelonephritis</title>
                     <text>
                        <paragraph>Among 2804 subjects who received PHEXX in Studies 1 and 2, 0.36% (n=10) reported adverse reactions of cystitis, pyelonephritis, or other upper urinary tract infection (UTI). Of these, one case of pyelonephritis was considered serious and required hospitalization. Avoid use of PHEXX in females of reproductive potential with a history of recurrent urinary tract infection or urinary tract abnormalities.</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="75854345-c0b0-4b9d-a8e2-d2778371e5d8"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Cystitis and Pyelonephritis [<content styleCode="italics">see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>
                        </content>]</item>
                  </list>
               </text>
               <effectiveTime value="20250502"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (≥2%) were vulvovaginal burning sensation, vulvovaginal pruritus, vulvovaginal mycotic infection, urinary tract infection, vulvovaginal discomfort, bacterial vaginosis, vaginal discharge, genital discomfort, dysuria, and vulvovaginal pain. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Evofem at toll-free phone 1-833-EVFMBIO or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="613192ad-2f88-4cf3-8b00-afff9de7abe7"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety of PHEXX (pre-filled applicator with 5-gram dose) has been evaluated in two clinical trials (Study 1 and Study 2) in 2804 subjects (over 19,000 cycles of exposure). The racial/ethnic distribution was 66% White, 27% Black or African American, 2% Asian, 1% American Indian or Alaska Native, 0.3% Native Hawaiian or Pacific Islander, and 5% other; 32% of the study population was Hispanic. Study 1 included a one-year extension phase where 342 U.S. subjects were exposed to PHEXX for 13 cycles.</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                     <component>
                        <section>
                           <id root="8c466b1b-30b0-4761-adc3-30fdc3fb5c93"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Hypersensitivity Reaction</content>
                              </paragraph>
                              <paragraph>Of the 2804 PHEXX-treated subjects in Studies 1 and 2, one subject reported a suspected drug hypersensitivity. Avoid PHEXX use in females of reproductive potential with suspected hypersensitivity to the ingredients in PHEXX.</paragraph>
                              <paragraph>The most common adverse reactions (≥10%) in the U.S. population in Studies 1 and 2 (n=2480) were: vulvovaginal burning sensation (18.0%) and vulvovaginal pruritus (14.5%). The majority of these adverse reactions were mild and few led to discontinuation. Table 1 summarizes the most common adverse reactions (≥2%) reported by subjects using PHEXX in the U.S.</paragraph>
                              <table width="75%" ID="Table1">
                                 <caption>Table 1. Adverse Reactions that Occurred in ≥2% of Subjects Who Used PHEXX to Prevent Pregnancy (Studies 1 and 2 – U.S. population only)</caption>
                                 <col width="80%" align="left" valign="bottom"/>
                                 <col width="20%" align="center" valign="bottom"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule">Adverse Reaction</th>
                                       <th styleCode="Rrule">PHEXX<br/>(N=2480)<br/>(%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule">Vulvovaginal Burning Sensation</td>
                                       <td styleCode="Rrule">18.0</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule">Vulvovaginal Pruritus</td>
                                       <td styleCode="Rrule">14.5</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule">Vulvovaginal Mycotic Infection<footnote>Includes preferred terms (PT) vulvovaginal mycotic infection and vulvovaginal candidiasis.</footnote>
                                       </td>
                                       <td styleCode="Rrule">9.1</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule">Urinary Tract Infection<footnote>Includes PTs urinary tract infection, streptococcal urinary tract infection, Escherichia urinary tract infection, and urinary tract infection bacterial.</footnote>
                                          <footnote>Does not include PTs cystitis, kidney infection, and pyelonephritis [<content styleCode="italics">see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>
                                             </content>].</footnote>
                                       </td>
                                       <td styleCode="Rrule">9.0</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule">Vulvovaginal Discomfort</td>
                                       <td styleCode="Rrule">9.0</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule">Bacterial Vaginosis</td>
                                       <td styleCode="Rrule">8.4</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule">Vaginal Discharge</td>
                                       <td styleCode="Rrule">5.5</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule">Genital Discomfort</td>
                                       <td styleCode="Rrule">4.1</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule">Dysuria</td>
                                       <td styleCode="Rrule">3.1</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule">Vulvovaginal Pain</td>
                                       <td styleCode="Rrule">2.1</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Among subjects who used PHEXX in Studies 1 and 2, 1.6% discontinued from the clinical trials due to an adverse reaction. The most common adverse reactions leading to study discontinuation were vulvovaginal burning sensation (0.7%); and vulvovaginal pruritus and vulvovaginal discomfort (0.1% each).</paragraph>
                           </text>
                           <effectiveTime value="20250502"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d98990da-39a8-4e58-9691-8fe472e01cf8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Male Partners</content>
                              </paragraph>
                              <paragraph>Among male partners of subjects who used PHEXX for contraception in Study 2, 9.8% (131 of 1330) reported symptoms of local discomfort (burning, itching, pain, and "other"). Of these local discomfort symptoms, 74.7% were mild, 21.4% were moderate, and 3.9% were severe. Two subjects discontinued participation in the study due to male partner symptoms.</paragraph>
                           </text>
                           <effectiveTime value="20250502"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="5c660efe-9b95-4b92-be59-5d8664a92734"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250502"/>
               <component>
                  <section ID="S8.1">
                     <id root="7253666b-83d6-4eab-a420-daa1d2682084"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250502"/>
                     <component>
                        <section>
                           <id root="a111ab91-7936-44f0-be99-05db37737541"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no use for PHEXX in pregnancy; therefore, discontinue PHEXX during pregnancy. There are no data with the use of PHEXX in pregnant women or animals. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250502"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="75fe1ef4-447f-41c6-953d-7368848a0b13"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250502"/>
                     <component>
                        <section>
                           <id root="e5c99b5a-9e2b-4810-bcd7-b23049aa8f6d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of lactic acid, citric acid, and potassium bitartrate or their metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.</paragraph>
                           </text>
                           <effectiveTime value="20250502"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="cdd8f756-0e14-410f-983e-25cf6a9bb9f9"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of PHEXX have been established in females of reproductive potential. Efficacy is expected to be the same for post-menarchal females under the age of 17 as for users 17 years and older. The use of PHEXX before menarche is not indicated.</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="da5abaa1-bb6a-4c75-a815-87bcd5599633"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>PHEXX (lactic acid, citric acid, and potassium bitartrate) is a vaginal gel.</paragraph>
                  <paragraph>PHEXX is an off-white to tan in color gel of uniform consistency, containing three active ingredients: lactic acid, citric acid, and potassium bitartrate.</paragraph>
                  <paragraph>The structural formula for lactic acid is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Lactic acid is designated chemically as 2-hydroxypropanoic acid with an empirical formula of C<sub>3</sub>H<sub>6</sub>O<sub>3</sub> and a molecular weight of 90.08 g/mol.</paragraph>
                  <paragraph>The structural formula for citric acid is:</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph>Citric acid is designated chemically as 2-hydroxypropane-1,2,3-tricarboxylic acid with an empirical formula of C<sub>6</sub>H<sub>8</sub>O<sub>7</sub> and a molecular weight of 192.124 g/mol.</paragraph>
                  <paragraph>The structural formula for potassium bitartrate is:</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph>Potassium bitartrate is designated chemically as potassium; (2<content styleCode="italics">R</content>, 3<content styleCode="italics">R</content>)-2,3,4-trihydroxy-4-oxobutanoate with an empirical formula of KC<sub>4</sub>H<sub>5</sub>O<sub>6</sub> and a molecular weight of 188.177 g/mol.</paragraph>
                  <paragraph>Each 5 gram dose is provided in a pre-filled single-dose applicator containing lactic acid USP (1.8% w/w), citric acid USP (1% w/w), and potassium bitartrate USP (0.4% w/w). Inactive ingredients present in the gel are: glycerin, alginic acid, xanthan gum, sodium hydroxide, benzoic acid, and purified water.</paragraph>
               </text>
               <effectiveTime value="20250502"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phexx-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phexx-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phexx-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="a7b7aeb7-fed5-4ddb-8e41-7995602fc75b"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250502"/>
               <component>
                  <section ID="S12.1">
                     <id root="59606b1c-3d97-4d68-ab41-f1da6e842768"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>In <content styleCode="italics">in vitro</content> studies, PHEXX produced a normal vaginal pH range (pH 3.5 – 4.5) in the presence of semen. In clinical studies, post-coital testing demonstrated pH &lt;5 in the majority of subjects, and sperm motility reduction.</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="b9bf8d35-0635-4b88-ac4b-a20e47229fd8"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Pharmacodynamic studies in humans have not been performed.</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="bc8ca632-d150-43ab-b27b-52f7cc584996"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Pharmacokinetic studies in humans have not been performed. Systemic exposures of lactic acid, citric acid, and potassium bitartrate following vaginal administration of PHEXX are not expected to lead to safety concerns.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content> studies with commonly used vaginal preparations (miconazole, metronidazole, tioconazole, and a product for maintaining normal vaginal pH) showed no significant effect on the pH or buffering capacity of PHEXX.</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="7d123480-2554-4c7f-aa2f-3654c3009668"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250502"/>
               <component>
                  <section ID="S13.1">
                     <id root="d6ab888c-d8c8-4cc9-a38c-b46b654530e7"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20250502"/>
                     <component>
                        <section>
                           <id root="5c1b6ebb-3174-4de3-a204-9b151b21cc3c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Long-term carcinogenicity studies have not been performed with PHEXX.</paragraph>
                           </text>
                           <effectiveTime value="20250502"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="0b430e4b-60c1-4862-bd15-2c741f37cc0e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Mutagenic studies have not been performed with PHEXX.</paragraph>
                           </text>
                           <effectiveTime value="20250502"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="13291fef-2391-4f02-b86d-484e845eb210"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Reproductive studies have not been performed with PHEXX. Upon discontinuation of PHEXX, pregnancy may occur.</paragraph>
                           </text>
                           <effectiveTime value="20250502"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="ab436984-5a5f-45de-82df-f66e59f91662"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of PHEXX for the prevention of pregnancy was evaluated in a multi-center, open-label, single-arm clinical trial in the United States (AMP002; NCT03243305). The study enrolled females of reproductive potential 18 to 35 years of age with regular menstrual cycles (21 to 35 days). The median age was 27.8 years. The racial distribution was 70.6% White, 23.7% Black or African American, 2.5% Asian, 0.4% American Indian or Alaska Native, 0.2% Native Hawaiian or Pacific Islander, and 2.7% other. Subjects agreed to engage in at least 3 acts of heterosexual, vaginal intercourse per cycle. Subjects self-administered a 5 gram dose of PHEXX intravaginally up to one hour before each episode of intercourse for up to 7 cycles.</paragraph>
                  <paragraph>The primary efficacy endpoint was the 7-cycle typical use cumulative pregnancy rate as derived by Kaplan-Meier life-table analysis. A total of 101 on-treatment pregnancies occurred in 1183 subjects contributing 4769 evaluable natural cycles. The 7-cycle cumulative pregnancy rate was 13.7% (95% CI: 10.0%, 17.5%), excluding cycles with back-up contraception, cycles &lt;21 days or &gt;35 days in length and cycles in which no intercourse was reported. The estimated Pearl Index, calculated based on data from the 7-cycle study, was 27.5 (95% CI: 22.4%, 33.5%).</paragraph>
               </text>
               <effectiveTime value="20250502"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="4e9be402-64d7-4949-9171-1f1a440737ed"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>PHEXX (lactic acid, citric acid, and potassium bitartrate) vaginal gel is an off-white to tan color gel of uniform consistency containing lactic acid (1.8%), citric acid (1%), and potassium bitartrate (0.4%), supplied as individually wrapped 5 gram pre-filled single-dose vaginal applicators in sealed foil pouches along with a plunger, and are available as follows:</paragraph>
                  <table width="65%" styleCode="Noautorules">
                     <col width="55%" align="left" valign="top"/>
                     <col width="45%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>
                              <list listType="unordered" styleCode="disc">
                                 <item>NDC 69751-101-12</item>
                              </list>
                           </td>
                           <td>Box of 12 units</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250502"/>
               <component>
                  <section>
                     <id root="be9dec19-7118-40bd-8cc3-98ea26276992"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store in the original foil pack at room temperature 20°C to 25°C (68°F to 77°F); excursion permitted between 15°C to 30°C (59°F to 86°F) [<content styleCode="italics">see USP Controlled Room Temperature</content>].</paragraph>
                     </text>
                     <effectiveTime value="20250502"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="2b35f2f1-4c33-4d5d-9541-78c82c0e8311"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the Patient Information and FDA-approved patient labeling (Instructions for Use). Advise the patient:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>To intravaginally administer the contents of one pre-filled single-dose applicator of PHEXX before <content styleCode="bold underline">each</content> episode of vaginal intercourse and to administer an additional dose if intercourse does not occur within one hour of administration [<content styleCode="italics">see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>
                        </content>].</item>
                     <item>To consult their healthcare provider for severe or prolonged genital irritation [<content styleCode="italics">see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>
                        </content>].</item>
                     <item>To discontinue PHEXX if they develop a local hypersensitivity reaction [<content styleCode="italics">see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>
                        </content>].</item>
                     <item>To contact their healthcare provider if experiencing urinary tract symptoms [<content styleCode="italics">see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>
                        </content>].</item>
                     <item>That PHEXX does not protect against HIV infection and other sexually transmitted infections.</item>
                  </list>
               </text>
               <effectiveTime value="20250502"/>
            </section>
         </component>
         <component>
            <section>
               <id root="19fd3e8d-ed0f-4592-81d4-a4235da041ac"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured for Evofem, Inc., a wholly owned subsidiary of Evofem Biosciences, Inc., San Diego, CA 92130</paragraph>
                  <paragraph>© 2025 Evofem, Inc.<br/>U.S. Patents 6,706,276 and 10,568,855</paragraph>
                  <paragraph>All rights reserved.<br/>PN-5067 R01</paragraph>
               </text>
               <effectiveTime value="20250502"/>
            </section>
         </component>
         <component>
            <section>
               <id root="5893b82d-989f-47f9-b846-e30110b97ddf"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>PATIENT INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">PHEXX<sup>®</sup> (FEX)<br/>(lactic acid, citric acid, and potassium bitartrate) vaginal gel</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Vaginal Use Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is PHEXX?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>PHEXX is a prescription medicine used to prevent pregnancy in females who can become pregnant and choose to use an on-demand method of birth control.</item>
                     <item>PHEXX is not effective at preventing pregnancy when used <content styleCode="bold">after</content> vaginal sex.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">How well does PHEXX work?</content>
                  </paragraph>
                  <paragraph>Your chance of getting pregnant depends on how well you follow the directions for using PHEXX. The better you follow the directions, the less chance you have of getting pregnant. It is very important that you follow the directions carefully <content styleCode="bold">each time</content> you have vaginal sex.</paragraph>
                  <paragraph>PHEXX does not protect against HIV infection or other sexually transmitted infections (STIs).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Before using PHEXX, tell your healthcare provider about all of your medical conditions, including if you:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>are pregnant or think you are pregnant. PHEXX is not for use in pregnant women.</item>
                     <item>are breastfeeding or plan to breastfeed. It is not known if PHEXX passes into your breast milk.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                  <paragraph>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I use PHEXX?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>See the <content styleCode="bold">
                           <linkHtml href="#IFU">Instructions for Use</linkHtml>
                        </content> that come with PHEXX for detailed instructions on the right way to use PHEXX.</item>
                     <item>Use PHEXX exactly as your healthcare provider tells you to use it.</item>
                     <item>PHEXX must be used <content styleCode="bold">before</content> vaginal sex.</item>
                     <item>PHEXX comes as a pre-filled single-dose vaginal applicator.</item>
                     <item>Insert 1 PHEXX pre-filled applicator into your vagina and use PHEXX <content styleCode="bold">within 1 hour before each time</content> you have vaginal sex. If you do not have vaginal sex within 1 hour of using PHEXX, you must insert a new PHEXX pre-filled applicator.</item>
                     <item>If you have vaginal sex more than 1 time within 1 hour, you must use a new PHEXX pre-filled applicator.</item>
                     <item>PHEXX may be used at any time during the menstrual cycle.</item>
                     <item>PHEXX may be used as soon as your healthcare provider tells you it is safe for you to have vaginal sex after childbirth, abortion, or miscarriage.</item>
                     <item>PHEXX may be used with hormonal contraceptives; and latex, polyurethane, and polyisoprene condoms. PHEXX may be used with a vaginal diaphragm. Avoid using PHEXX with contraceptive vaginal rings.</item>
                     <item>PHEXX may be used with other medicines used in the vagina to treat infections including miconazole, metronidazole, and tioconazole.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of PHEXX?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PHEXX may cause serious side effects, including:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">Bladder infection (cystitis) and acute kidney infection (pyelonephritis).</content> Urinary tract infections are common but can also be serious. You should not use PHEXX if you have a history of urinary tract infections that keep coming back or other problems with your urinary tract. Call your healthcare provider if you have burning with urination or other signs and symptoms of a urinary tract infection such as: burning feeling when passing urine, urine that looks cloudy, pain in the pelvis, or back pain.</item>
                     <item>
                        <content styleCode="bold">Allergic reactions.</content> Avoid using PHEXX if you are a female who can become pregnant and are allergic to lactic acid, citric acid, potassium bitartrate or any of the ingredients in PHEXX; <content styleCode="bold">or</content> your sexual partners are allergic to any of the ingredients in PHEXX. Stop using PHEXX if you have a local vulvovaginal reaction.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">The most common side effects of PHEXX include:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>vaginal burning</item>
                     <item>vaginal itching</item>
                     <item>vaginal yeast infection</item>
                     <item>discomfort around the vaginal area</item>
                     <item>bacterial vaginosis</item>
                     <item>vaginal discharge</item>
                     <item>discomfort in the genital area</item>
                     <item>pain while passing urine</item>
                  </list>
                  <paragraph>These are not all the possible side effects of PHEXX.</paragraph>
                  <paragraph>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store PHEXX?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Store PHEXX at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                     <item>Store PHEXX in the original foil pouch.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep PHEXX and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about the safe and effective use of PHEXX.</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes used for purposes other than those listed in a Patient Information leaflet. Do not use PHEXX for a condition for which it was not prescribed. Do not give PHEXX to other people, even if they have the same symptoms that you have. It may harm them.</paragraph>
                  <paragraph>You can ask your healthcare provider or pharmacist for information about PHEXX that is written for health professionals.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in PHEXX?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active ingredients:</content> lactic acid, citric acid, and potassium bitartrate</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive ingredients:</content> glycerin, alginic acid, xanthan gum, sodium hydroxide, benzoic acid, and purified water</paragraph>
                  <paragraph>For more information, go to www.phexx.com or call 1-833-EVFMBIO.</paragraph>
                  <paragraph>Manufactured for Evofem, Inc., a wholly owned subsidiary of Evofem Biosciences, Inc.</paragraph>
                  <paragraph>Unless otherwise indicated, all trademarks used herein are the property of Evofem Biosciences, Inc.</paragraph>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>© 2025 Evofem, Inc.<br/>All rights reserved.</paragraph>
                  <paragraph>Issued: April 2025<br/>PN-5067 R01</paragraph>
               </text>
               <effectiveTime value="20250502"/>
            </section>
         </component>
         <component>
            <section ID="IFU">
               <id root="f850d952-a694-4ea9-bf1b-9f3fba87be9d"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>INSTRUCTIONS FOR USE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">PHEXX<sup>®</sup> (FEX)<br/>(lactic acid, citric acid, and potassium bitartrate) vaginal gel</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Vaginal Use Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">These Instructions for Use contain information on how to use PHEXX vaginal gel.</content>
                  </paragraph>
                  <paragraph>Make sure that you read, understand, and follow the Instructions for Use before using PHEXX and each time you get a refill. There may be new information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Contents:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Each box contains 12 foil pouches.</item>
                     <item>Each foil pouch contains a pre-filled applicator and plunger rod (see <linkHtml href="#FigA">Figure A</linkHtml>).</item>
                     <item>Each pre-filled applicator contains 1 dose of PHEXX for 1-time use (single use).</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="center" valign="bottom"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold" ID="FigA">Figure A</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM4"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Important Information You Need to Know Before Using PHEXX</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Use 1 dose of PHEXX <content styleCode="bold">within 1 hour</content> before you have vaginal sex.</item>
                     <item>A new PHEXX pre-filled applicator must be used <content styleCode="bold">each time</content> you have vaginal sex. If you have vaginal sex more than 1 time within 1 hour, <content styleCode="bold">a new PHEXX pre-filled applicator must be used</content>.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Prepare to Use PHEXX</content>
                  </paragraph>
                  <paragraph>Keep the pre-filled applicator and plunger rod in the foil pouch until you are ready to use PHEXX.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 1: Wash Your Hands</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Wash your hands with soap and water before opening the foil pouch.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Step 2: Remove the Pre-filled Applicator and Plunger Rod from the Foil Pouch</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Remove the pre-filled applicator and plunger rod from the foil pouch (see <linkHtml href="#FigB">Figure B</linkHtml>)<content styleCode="italics">.</content>
                     </item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="center" valign="top"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold" ID="FigB">Figure B</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM5"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Important:</content> Do not remove the pink cap until instructed in Step 4.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Insert PHEXX Gel</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 3: Insert the Plunger Rod</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Gently and slowly insert the plunger rod into the pre-filled applicator. Push until you feel the tip of the plunger rod connect to the inside of the pre-filled applicator (see <linkHtml href="#FigC">Figure C</linkHtml>).</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="center" valign="top"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold" ID="FigC">Figure C</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM6"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">Do not</content> push hard or continue to push after the tip of the plunger rod connects to the inside of the pre-filled applicator. This could cause the gel to go into the pink cap.</item>
                     <item>Use a new pre-filled applicator if the gel goes into the pink cap.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Step 4: Remove the Pink Cap</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>After the plunger rod is connected to the pre-filled applicator, remove the pink cap from the pre-filled applicator (see <linkHtml href="#FigD">Figure D</linkHtml>).</item>
                     <item>The extra space between the gel and the end of the pre-filled applicator is normal.</item>
                     <item>The pre-filled applicator is now ready for use.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="center" valign="top"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold" ID="FigD">Figure D</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM7"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Step 5: Insert the PHEXX Pre-filled Applicator into the Vagina</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Hold the pre-filled applicator at the grooved area closest to the plunger rod (see <linkHtml href="#FigE">Figure E</linkHtml>).</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="center" valign="top"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold" ID="FigE">Figure E</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM8"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="disc">
                     <item>Gently insert the pre-filled applicator into the vagina as far as it will comfortably go while you continue to hold it by the grooved area firmly. This can be done sitting with your knees apart, lying on your back with your knees bent (see <linkHtml href="#FigF">Figure F</linkHtml>), or while standing with your feet apart or knees bent.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="center" valign="top"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold" ID="FigF">Figure F</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM9"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Step 6: Insert PHEXX Gel</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>While the pre-filled applicator is inserted in your vagina, use your index finger to push the plunger rod down until it stops. This is to make sure you receive the entire dose of PHEXX (see <linkHtml href="#FigG">Figure G</linkHtml>).</item>
                     <item>It is normal for a small amount of gel to be left in the applicator. You will still get the right dose.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="center" valign="top"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold" ID="FigG">Figure G</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM10"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Step 7: Remove the Used PHEXX Pre-filled Applicator</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Gently remove the plunger rod and pre-filled applicator from the vagina (see <linkHtml href="#FigH">Figure H</linkHtml>) and throw away (dispose of) the used pre-filled applicator.</item>
                     <item>PHEXX should be used <content styleCode="bold">within 1 hour before each time you have vaginal sex</content>. Use a new pre-filled applicator if you do not have vaginal sex within 1 hour of inserting PHEXX gel and you still plan to have vaginal sex.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100%" align="center" valign="top"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold" ID="FigH">Figure H</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM11"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Disposing of PHEXX</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 8: Throw Away (Dispose of) the Used PHEXX Pre-filled Applicator</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Used PHEXX pre-filled applicators and caps should be disposed of in the trash. The cap may be a potential choking hazard.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Storing PHEXX</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Store PHEXX at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                     <item>Store PHEXX in the original foil pouch.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep PHEXX and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>These Instructions for Use have been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>For more information, including full prescribing information and information on patient safety, go to www.phexx.com or call 1-833-EVFMBIO.</paragraph>
                  <paragraph>Manufactured for Evofem, Inc., a wholly owned subsidiary of Evofem Biosciences, Inc.</paragraph>
                  <paragraph>© 2025 Evofem, Inc. All rights reserved.</paragraph>
                  <paragraph>Issued: April 2025</paragraph>
               </text>
               <effectiveTime value="20250502"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>Figure A</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phexx-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Figure B</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phexx-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Figure C</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phexx-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Figure D</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phexx-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>Figure E</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phexx-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>Figure F</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phexx-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM10">
                     <text>Figure G</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phexx-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM11">
                     <text>Figure H</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phexx-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="4c770db6-4ec0-4fd2-9270-2ff129a32242"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 12 Applicator Box</title>
               <text>
                  <paragraph>phexx<sub>®</sub>
                  </paragraph>
                  <paragraph>(lactic acid, citric acid, and<br/>potassium bitartrate) Vaginal Gel<br/>1.8%, 1%, 0.4%</paragraph>
                  <paragraph>NDC 69751-101-12<br/>PN-5065 R01</paragraph>
                  <renderMultiMedia referencedObject="MM12"/>
               </text>
               <effectiveTime value="20250502"/>
               <component>
                  <observationMedia ID="MM12">
                     <text>PRINCIPAL DISPLAY PANEL - 12 Applicator Box</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="phexx-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>